The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Open accessAbstract
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects.Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes.We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed in tumor endothelium and is activated by rosiglitazone in cultured endothelial cells.Furthermore, we show that rosiglitazone suppresses primary tumor growth and metastasis by both direct and indirect antiangiogenic effects.Rosiglitazone inhibits bovine capillary endothelial cell but not tumor cell proliferation at low doses in vitro and decreases VEGF production by tumor cells.In our in vivo studies, rosiglitazone suppresses angiogenesis in the chick chorioallantoic membrane, in the avascular cornea, and in a variety of primary tumors.These results suggest that PPARγ ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Self-citationPPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Biological Action of Leptin as an Angiogenic Factor
Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcı́a-Cardeña, G., Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P. J., et al. (1998) · Science · doi:10.1126/science.281.5383.1683 · Cited by 1,371
Sunderkötter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., & Sorg, C. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.3.410 · Cited by 1,120
Research works printed but not linked: 12
- Kubota, 1998, Cancer Res, 58, 3344
- 10.1210/jc.86.5.2170 · doi:10.1210/jc.86.5.2170
- Palakurthi, 2001, Cancer Res, 61, 6213
- Murata, 2000, Invest Ophthalmol Vis Sci, 41, 2309
- Inoue, 2001, Anticancer Res, 21, 2471
- Slaton, 1999, Clin Cancer Res, 5, 2726
- Masferrer, 2000, Cancer Res, 60, 1306
- Browder, 2000, Cancer Res, 60, 1878
- Pihan, 1998, Cancer Res, 58, 3974
- Drixler, 2000, Cancer Res, 60, 1761
- 10.1172/JCI9023 · doi:10.1172/jci9023
- Fahmi, 2002, J Rheumatol, 29, 3
Cited by
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Self-citationMechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Angiogenesis modulates adipogenesis and obesity
Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32239 · Cited by 736
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
FOLKMAN, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 658
Self-citationMarx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470
Self-citationAntineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Regulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 413
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Gately, S., & Li, W. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.040 · Cited by 398
Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis
Fukumura, D., Ushiyama, A., Duda, D. G., Xu, L., Tam, J., Krishna, V., Chatterjee, K., Garkavtsev, I., & Jain, R. K. (2003) · Circulation Research · doi:10.1161/01.res.0000099243.20096.fa · Cited by 365
Le Jan, S., Amy, C., Cazes, A., Monnot, C., Lamandé, N., Favier, J., Philippe, J., Sibony, M., Gasc, J.-M., Corvol, P., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64285-x · Cited by 346
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
“PPAR is highly expressed in vascular endothelial cells and is lost on exposure to TZD, suggesting that the antiangiogenic properties of PPAR ligands may play a role in inducing an antineoplastic effect.(11) The effective concentration of Table 1.”
BackgroundEndogenous angiogenesis inhibitors
FOLKMAN, J. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Self-citationRegulation of inflammation in cancer by eicosanoids
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.08.004 · Cited by 303
Self-citationEpoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E., Barnés, C. M., Mammoto, A., Mammoto, T., Luria, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58128 · Cited by 294
Self-citationAmeshima, S., Golpon, H., Cool, C. D., Chan, D., Vandivier, R. W., Gardai, S. J., Wick, M., Nemenoff, R. A., Geraci, M. W., & Voelkel, N. F. (2003) · Circulation Research · doi:10.1161/01.res.0000073585.50092.14 · Cited by 292
Panigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., & Kieran, M. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711281105 · Cited by 269
Self-citationEmerging roles of aerobic glycolysis in breast cancer
Wu, Z., Wu, J., Zhao, Q., Fu, S., & Jin, J. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02187-8 · Cited by 255
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis
Olivares, C., Ricci, A., Bilotas, M., Barañao, R. I., & Meresman, G. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.063 · Cited by 65
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
FastProject: a tool for low-dimensional analysis of single-cell RNA-Seq data
DeTomaso, D., & Yosef, N. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1176-5 · Cited by 58
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37
Mihalyi, A., Mutinda, K. C., Simsa, P., Debrock, S., Mwenda, J. M., & D’Hooghe, T. M. (2005) · Therapy · doi:10.2217/14750708.2.4.623 · Cited by 22
Sinagra, T., Tamburella, A., Urso, V., Siarkos, I., Drago, F., Bucolo, C., & Salomone, S. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.013 · Cited by 18
Metadata
- Authors
- Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., Fletcher, J. A., Hlatky, L., Hahnfeldt, P., Folkman, J., & Kaipainen, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 923-932
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4240908764
- Cited by
- 276
- References
- 35
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.